■微RNA(miRNA)有望作为生殖细胞肿瘤(GCT)的血液肿瘤标志物,miRNA-371-3p是研究最多的。包括其他候选miRNAs以帮助治疗睾丸GCTs的边际益处仍不清楚。
■评估我们的联合miRNA测定(371a-3p和372-3p)在具有临床局部睾丸肿块的患者中的性能。
■这是一项前瞻性纳入正在进行的方案的患者的回顾性研究,收集血清miR-371a-3p和miR-372-3p水平(一起,纪念斯隆·凯特琳癌症中心[MSK]miRNA测定[MMA])在疑似或诊断为睾丸GCT的患者中。
■感兴趣的主要结果是miR-371a-3p和372-3p的敏感性和特异性,单独和一起,在睾丸切除术标本中检测非畸胎性GCTs。次要结果包括其他测定诊断参数,患者和疾病因素与miRNA水平变化的关系,睾丸切除术后miRNA正常化的时间模式。
■纳入了62例患者,52在睾丸切除术中有可行的GCT,10人没有癌症或非GCT。46例GCT患者睾丸前MMA阳性(敏感性88.5%[95%置信区间{CI}:79.8,97.2]),1例患者睾丸前MMA阳性,但无GCT(特异性90.0%[95%CI:71.4,100]).miR-371a-3-p和miR-372-3p的诊断性能相似。miRNA降低到不可检测水平的时间各不相同,一些患者在睾丸切除术后长达3周的阳性水平。
■生物标志物miR-371a-3p和miR-372-3p对局部睾丸GCT表现出高灵敏度和特异性,但单个患者的相对miRNA水平和正常化时间的变化原因尚不清楚。
■我们研究了基于血液的生物标志物miR-371a-3p和miR-372-3p在睾丸小肿块患者中检测睾丸癌(生殖细胞肿瘤)的能力。我们发现,这些对睾丸癌都是敏感和特异的。
UNASSIGNED: MicroRNAs (miRNAs) show promise as blood-based tumor markers for germ cell tumors (GCTs), with miRNA-371-3p being the most studied. The marginal benefit of including other candidate miRNAs to aid with the management of testicular GCTs remains unclear.
UNASSIGNED: To assess the performance of our combined miRNA assay (371a-3p and 372-3p) in patients with clinically localized testicular masses.
UNASSIGNED: This was a retrospective review of patients prospectively enrolled in an ongoing protocol collecting serum miR-371a-3p and miR-372-3p levels (together, Memorial Sloan Kettering Cancer Center [MSK] miRNA assay [MMA]) in patients with a suspected or diagnosed testicular GCT.
UNASSIGNED: The coprimary outcomes of interest were sensitivity and specificity of miR-371a-3p and 372-3p, individually and together, to detect nonteratomatous GCTs in the orchiectomy specimen. Secondary outcomes included additional assay diagnostic parameters, the relationship of patient and disease factors with variations in miRNA levels, and temporal patterns of miRNA normalization after orchiectomy.
UNASSIGNED: Sixty-two patients were included, 52 had a viable GCT at orchiectomy, and ten had no cancer or a non-GCT. Forty-six patients with a GCT had positive preorchiectomy MMA (sensitivity 88.5% [95% confidence interval {CI}: 79.8, 97.2]), and one patient had positive preorchiectomy MMA but no GCT (specificity 90.0% [95% CI: 71.4, 100]). The diagnostic performance of miR-371a-3-p and miR-372-3p was similar. The time for miRNA to decrease to undetectable levels varied, with some patients having positive levels up to 3 wk after orchiectomy.
UNASSIGNED: The biomarkers miR-371a-3p and miR-372-3p demonstrated high sensitivity and specificity for localized testicular GCTs, but causes of variation in relative miRNA levels and time to normalization for individual patients remain unclear.
UNASSIGNED: We studied the ability of the blood-based biomarkers miR-371a-3p and miR-372-3p to detect testicular cancer (germ cell tumors) in patients with small testicular masses. We found that together and individually these were sensitive and specific for testicular cancer.